[Studies on renal dysfunction after intra-arterial hypertensive chemotherapy (CDDP, PEP) for advanced cancer of the uterine cervix--serum.urinary alpha 1-microglobulin, beta 2-microglobulin and urinary lysozyme, albumin].
The present study evaluated the degree of renal impairment caused by intra-arterial hypertensive chemotherapy (CDDP, PEP). In 11 cases of advanced cancer of the uterine cervix, serum and urinary levels of alpha 1-microglobulin (alpha 1-m) and beta 2-microglobulin (beta 2-m), and urinary albumin (Alb) and lysozyme (LZM) were determined before the chemotherapy and 1,2 and 3 weeks after the therapy. Results are summarized as follows: 1. After intra-arterial chemotherapy, the histological classification was Grade I in 1 case (9.1%), Grade IIa in 2 cases (18.2%), and Grade IIb in 8 cases (72.7%). 2. Serum alpha 1-m and beta 2-m levels remained within the normal range after chemotherapy. 3. Urinary alpha 1-m, beta 2-m and LZM levels exceeded the normal limit between 1 and 2 weeks after the therapy, but thereafter they returned to normal. 4. Urinary Alb was significantly increased (p less than 0.05) between 1 and 2 weeks after therapy, but thereafter it returned to normal. These results suggested that intra-arterial chemotherapy (CDDP 100mg and PEP 40 mg in a dose) was effective for advanced cancer of the cervix and that renal disorders including tubular and glomerular impairment, which are the adverse effects of the therapy, were mild and reversible.
Iwanari
O
O
Department of Obstetrics and Gynecology, Shimane Medical University.
Date
Y
Y
Yoshino
N
N
Miyako
J
J
Ryuhkoh
K
K
Moriyama
M
M
Nakayama
S
S
Kitao
M
M
D000328:Adult; D000368:Aged; D000419:Albuminuria / Q000139:chemically induced* / Q000652:urine; D000510:Alpha-Globulins / Q000378:metabolism* / Q000652:urine; D000804:Angiotensin II / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D001794:Blood Pressure / Q000187:drug effects*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D008875:Middle Aged; D009113:Muramidase / Q000652:urine*; D017663:Peplomycin; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D001613:beta 2-Microglobulin / Q000378:metabolism* / Q000652:urine
D000510:Alpha-Globulins; C016001:alpha-1-microglobulin; D001613:beta 2-Microglobulin; D001761:Bleomycin; D000804:Angiotensin II; D017663:Peplomycin; D009113:Muramidase; D002945:Cisplatin